What changed in ADPKD evidence this week and last

Key new evidence this run

• GLPG2737 / CFTR inhibition failed in the phase 2a MANGROVE study: it did not reduce htTKV growth or slow eGFR decline versus placebo in rapidly progressive ADPKD (PMID42201338).
• A tolvaptan-treated ADPKD biomarker study found urinary beta2-microglobulin tracked faster eGFR decline and greater structural severity better than MCP-1, NGAL, or KIM-1 (PMID42209684).
• Preclinical work expanded the mechanistic map: HIF-1a-regulated Pannexin-1 drove luminal ATP accumulation in cysts (PMID42117913), and a repurposing screen nominated salicylic acid, birinapant, and bardoxolone methyl as candidates (PMID42184822).

Four-track review outcome

What strengthened

• The negative CFTR result cleaned up a weak hypothesis.
• Biomarker interpretation under tolvaptan got more specific.
• The mechanistic map expanded around HIF/ATP signaling.

What weakened

• Any claim that CFTR inhibition is already a disease-modifying ADPKD strategy.
• Any assumption that all urinary injury markers are equally useful under tolvaptan.

Key new evidence this run

• Pregnancy history in HALT-PKD was not clearly associated with faster ADPKD progression (PMID42149684).
• Pediatric ADPKD data now link higher BP states and cyst burden to LV remodeling, with cyst burden independently predicting LVMI (PMID42151644).
• New preclinical ADPKD work showed MQ232 attenuated PKD in Pkd1RC/RC mice similarly to tolvaptan, while Pkd2 mutant kidneys showed reduced tubule flow and functional reserve rather than simple obstruction (PMID42176774; PMID42176282).

Four-track review outcome

What strengthened

• The pregnancy-progression question is less dire than the common assumption.
• Pediatric risk framing now has a clearer cyst-burden component.
• The mechanistic map expanded, especially around V2R pharmacology and Pkd2 flow biology.

What weakened

• Any blanket claim that pregnancy necessarily accelerates ADPKD progression.
• Any claim that BP alone explains early pediatric cardiac remodeling.
• Any simple obstruction-only model for cystogenesis in Pkd2 disease.

Key new evidence this run

• Tolvaptan polyuria is now better characterized: a dedicated PROM study found measurable ADPKD-specific quality-of-life burden and better burden tracking with TIPS than with a generic urinary scale (PMID42114268).
• New mechanistic and model-building papers landed: PKD2 regulation by RASSF4 (PMID42141135), human kidney tubuloid cystogenesis modeling (PMID42115942), and a PubMed-indexed HDAC6 candidate paper for GV-001 (PMID41940800).
• ClinicalTrials.gov refreshed several tracked studies: ABBV-CLS-628 (NCT06902558), VX-407 / AGLOW (NCT07161037), PYC-003 (NCT06714006), and AZD1613 (NCT07228364).

Four-track review outcome

What strengthened

• Tolvaptan counseling can now be more specific because the polyuria burden is measured, not just assumed.
• Human-relevant preclinical modeling improved via tubuloids.
• Trial tracking fidelity improved with fresh registry updates.

What weakened

• Any claim that tolvaptan is easy to tolerate.
• Any claim that preclinical target discovery is close to a cure.

Key new evidence this run

• Tolvaptan gained a small supportive hemodynamic signal: improved nocturnal BP dipping and lower non-dipper prevalence in hypertensive ADPKD (PMID42050863).
• Prognostic stratification improved: adding KFRE to Mayo imaging/TKV performed better than imaging alone in adults with baseline eGFR <60 (PMID42027549).
• New preclinical pathway breadth expanded: apelin signaling (PMID41958979), ALDH1A1/disulfiram ± PD-L1 blockade (PMID41864666), ECS/CB1R dysregulation (PMID41840489), and CRISPRa delivery miniaturization for Pkd1 activation (PMID42068455).

Four-track review outcome

What strengthened

• Tolvaptan’s hemodynamic story is a bit better.
• Risk prediction looks more practical with MIC/TKV + KFRE.
• The preclinical target map got broader, which is useful for watchlist coverage.

What weakened

• Any claim that a single new preclinical pathway is near-term curative.
• Any claim that better prognostic modeling alone improves outcomes.
• Any claim that supportive hemodynamic benefit equals full renal disease-modification proof.